OBI Pharma - Asset Resilience Ratio

Latest as of June 2026: 6.83%

OBI Pharma (4174) has an Asset Resilience Ratio of 6.83% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4174 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

NT$183.70 Million

≈ $5.79 Million USD Cash + Short-term Investments

Total Assets

NT$2.69 Billion

≈ $84.75 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how OBI Pharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see OBI Pharma balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down OBI Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore OBI Pharma (4174) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$183.70 Million	6.83%
Total Liquid Assets	NT$183.70 Million	6.83%

Asset Resilience Insights

Limited Liquidity: OBI Pharma maintains only 6.83% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

OBI Pharma Industry Peers by Asset Resilience Ratio

Compare OBI Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for OBI Pharma (2011–2025)

The table below shows the annual Asset Resilience Ratio data for OBI Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.48%	NT$427.00 Million ≈ $13.45 Million	NT$3.42 Billion ≈ $107.79 Million	-12.26pp
2024-12-31	24.74%	NT$1.40 Billion ≈ $44.07 Million	NT$5.65 Billion ≈ $178.12 Million	-8.86pp
2023-12-31	33.60%	NT$1.88 Billion ≈ $59.33 Million	NT$5.60 Billion ≈ $176.55 Million	+33.13pp
2022-12-31	0.47%	NT$31.46 Million ≈ $991.23K	NT$6.63 Billion ≈ $209.00 Million	-2.69pp
2021-12-31	3.16%	NT$141.77 Million ≈ $4.47 Million	NT$4.49 Billion ≈ $141.36 Million	-4.02pp
2020-12-31	7.18%	NT$383.53 Million ≈ $12.08 Million	NT$5.34 Billion ≈ $168.23 Million	+7.16pp
2019-12-31	0.02%	NT$1.39 Million ≈ $43.92K	NT$5.66 Billion ≈ $178.42 Million	-38.95pp
2017-12-31	38.97%	NT$2.02 Billion ≈ $63.72 Million	NT$5.19 Billion ≈ $163.51 Million	+1.68pp
2016-12-31	37.29%	NT$2.36 Billion ≈ $74.34 Million	NT$6.33 Billion ≈ $199.37 Million	+4.71pp
2012-12-31	32.58%	NT$284.81 Million ≈ $8.97 Million	NT$874.17 Million ≈ $27.54 Million	-41.39pp
2011-12-31	73.97%	NT$386.65 Million ≈ $12.18 Million	NT$522.72 Million ≈ $16.47 Million	--

pp = percentage points

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$115.04 Million

NT$3.65 Billion TWD

Market Cap Rank

#18749 Global

#1015 in Taiwan

Share Price

NT$27.75

Change (1 day)

+4.13%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00